RESEARCH

Tasman Oncology Research Ltd is a patient focused research company dedicated to conducting clinical trials to help both insured and uninsured patients gain access to new oncology pharmaceuticals only accessible or affordable through a trial opportunity. Tasman Oncology Research is a well-resourced and well-published clinical trials unit; with a team of five clinical trial-coordinators and two data entry staff with their their own dedicated suite next to the day infusion unit.

CLINICAL TRIALS

Why do we participate in clinical trials?

Tasman Oncology Research Ltd is a patient focused research company dedicated to conducting clinical trials to help both insured and uninsured patients gain access to new oncology pharmaceuticals only accessible or affordable through a trial opportunity. All trial related consultations and procedures are provided at no cost to the patient. All research conducted by the Tasman Oncology Research is conducted in accordance with applicable regulatory requirements and the internationally recognised standards of Good Clinical Practice.

Through our close partnerships with clinical research organisations, we coordinate a number of Phase One, Two and Three multi-site international clinical trials which are outlined on the Current Clinical Trials page

If you would like more information regarding clinical trial opportunities, please speak with your doctor or one of our research coordinators. The coordinators can be reached directly on (07) 5613 2484, or research@tasmanhealthcare.com.au.

RESEARCH FACILITIES

Tasman Oncology Research brings together an experienced team of research coordinators, nurses, data managers and scientists to support an advanced clinical trial unit.

Our clinical trials unit is staffed by a highly qualified group of research coordinators who are certified in Good Clinical Practice through ARCS Australia and also hold IATA certification for the transportation of dangerous goods. All coordinators have extensive experience using IVRS/IWRS and eCRF systems. We have a dedicated Quality Manager on team ensuring compliance with ICH-GCP guidelines, TGA regulations, sponsor requirements, protocol requirements and Tasman Health Care SOPs. We have a strong working relationship with Bellberry HREC for efficient study start-up timelines and lead site responsibilities.

Staff are familiar and have up-to-date training in several eCRF platforms including InForm, Medidata RAVE, Oracle RDC and eClinical OS. They are collectively experienced in using patient electronic diaries and imaging transfer software including AGMedNet and Bioclinica.
In addition, the research coordinators have laboratory experience and are competent in all aspects of specimen collection, preparation, handling and shipping.

Tasman Oncology Research views continual education and training as a key investment strategy. Therefore we ensure staff are qualified to perform procedures through ongoing training and professional development. All investigators, sub-investigators and clinical research staff attend both internal and external compulsory training, as well as undertaking further education specific to the nature of this work.

Our monthly quality meetings monitor the need for training and Clinical Research staff conduct regular in-services on the requirements and conduct of clinical research. In particular the specific requirements of individual studies for staff from other departments involved in the conduct of clinical research.

CURRENTLY RECRUITING CLINICAL TRIALS

Please speak to your treating oncologist or GP to investigate whether there may be any current clinical trials you may be suitable for. The following clinical trials are currently open for recruitment:

CA224-020

A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors.
 clinicaltrials.gov/ct2/show/NCT01968109

MK3475-716

Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716)
https://clinicaltrials.gov/ct2/show/NCT03553836

There are currently no specific trials currently recruiting for this cancer type

There are currently no specific trials currently recruiting for this cancer type

There are currently no specific trials currently recruiting for this cancer type

There are currently no specific trials currently recruiting for this cancer type

There are currently no specific trials currently recruiting for this cancer type

TACTI-002

TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)

https://clinicaltrials.gov/ct2/show/NCT03625323?term=TACTI&rank=1 

TACTI-002

TACTI-002 (Two ACTive Immunotherapeutics): A Multicenter, Open Label, Phase II Study in Patients With Previously Untreated Unresectable or Metastatic Non-small Cell Lung Cancer (NSCLC), or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic Squamous Head and Neck Cancer (HNSCC) Receiving the Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) in Combination With Pembrolizumab (PD-1 Antagonist)

https://clinicaltrials.gov/ct2/show/NCT03625323?term=TACTI&rank=1

Please contact our research rooms on (07) 5613 2484 for further information, or follow the clinicaltrials.gov hyperlink for each particular study.